Brain, Vol. 123, No. 4, 733-745,
April 2000
© 2000 Oxford University Press
Hallucinations in Parkinson's disease
Prevalence, phenomenology and risk factors
1 Department of Neurology, Hôpital Tenon and 2 Department of Neurology, Hôpital Léopold Bellan, Paris, France
Correspondence to:
Dr G. Fénelon, Department of Neurology, Hôpital Tenon, 4 rue de la Chine, 75020 Paris, France E-mail: gilles.fenelon{at}tnn.ap-hop-paris.fr
Hallucinations, mainly of a visual nature, are considered to affect about one-quarter of patients with Parkinson's disease. They are commonly viewed as a side-effect of antiparkinsonian treatment, but other factors may be involved. The aim of this study was to determine the phenomenology, prevalence and risk factors of hallucinations in Parkinson's disease. Two-hundred and sixteen consecutive patients fulfilling clinical criteria for Parkinson's disease were studied. Demographic and clinical variables were recorded, including motor and cognitive status, depressive symptoms and sleep–wake disturbances. Patients with and without hallucinations were compared using non-parametric tests, and logistic regression was applied to significant data. Hallucinations had been present during the previous 3 months in 39.8% of the patients, and fell into three categories: minor forms, consisting of a sensation of a presence (person), a sideways passage (commonly of an animal) or illusions were present in 25.5% of the patients (an isolated occurrence in 14.3%), formed visual hallucinations were present in 22.2% (isolated in 9.3%) and auditory hallucinations were present in 9.7% (isolated in 2.3%). Patients with minor hallucinations had a higher depression score than non-hallucinators but did not differ in other respects. Logistic regression analysis identified three factors independently predictive of formed visual hallucinations: severe cognitive disorders, daytime somnolence and a long duration of Parkinson's disease. These findings indicate that, when minor hallucinations are included, the total prevalence is much higher than previously reported. A simple side-effect of dopaminergic treatment is not sufficient to explain the occurrence of all visual hallucinations. The main risk factor in treated patients is cognitive impairment, although sleep–wake cycle disturbances, and possibly other factors related to the duration of the disease, act as cofactors.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. W. Olanow, M. B. Stern, and K. Sethi The scientific and clinical basis for the treatment of Parkinson disease (2009) Neurology, May 26, 2009; 72(21_Supplement_4): S1 - S136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. K. Archibald, M. P. Clarke, U. P. Mosimann, and D. J. Burn The retina in Parkinson's disease Brain, May 1, 2009; 132(5): 1128 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Chen, D. P. Trombetta, and H. H. Fernandez Palliative Management of Parkinson Disease: Focus on Nonmotor, Distressing Symptoms Journal of Pharmacy Practice, August 1, 2008; 21(4): 262 - 272. [Abstract] [PDF]
|
|
|
|
 |
|
 W Poewe When a Parkinson's disease patient starts to hallucinate Practical Neurology, August 1, 2008; 8(4): 238 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D R Williams, J D Warren, and A J Lees Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism J. Neurol. Neurosurg. Psychiatry, June 1, 2008; 79(6): 652 - 655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Lertxundi, J. Peral, O. Mora, S. Domingo-Echaburu, M. J. Martinez-Bengoechea, and J. C. Garcia-Monco Antidopaminergic therapy for managing comorbidities in patients with Parkinson's disease Am. J. Health Syst. Pharm., March 1, 2008; 65(5): 414 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Weintraub and H. I. Hurtig Presentation and Management of Psychosis in Parkinson's Disease and Dementia With Lewy Bodies Am J Psychiatry, October 1, 2007; 164(10): 1491 - 1498. [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Kurz, A. Melissa Schlitter, Y. Klenk, T. Mueller, J. P. Larsen, D. Aarsland, and G. Dekomien FMR1 Alleles in Parkinson's Disease: Relation to Cognitive Decline and Hallucinations, A Longitudinal Study J Geriatr Psychiatry Neurol, June 1, 2007; 20(2): 89 - 92. [Abstract] [PDF]
|
|
|
|
|
|
S. Steinlechner, J. Stahlberg, B. Volkel, A. Djarmati, J. Hagenah, A. Hiller, K. Hedrich, I. Konig, C. Klein, and R. Lencer Co-occurrence of affective and schizophrenia spectrum disorders with PINK1 mutations J. Neurol. Neurosurg. Psychiatry, May 1, 2007; 78(5): 532 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Stewart NICE guideline for Parkinson's disease Age Ageing, May 1, 2007; 36(3): 240 - 242. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Ferreri, C. Agbokou, and S. Gauthier Recognition and management of neuropsychiatric complications in Parkinson's disease Can. Med. Assoc. J., December 5, 2006; 175(12): 1545 - 1552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Goetz, W. Fan, S. Leurgans, B. Bernard, and G. T. Stebbins The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol, May 1, 2006; 63(5): 713 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Samuel, I. Maidment, M. Boustani, and C. Fox Clinical management of Parkinson's disease dementia: pitfalls and progress Advan. Psychiatr. Treat., March 1, 2006; 12(2): 121 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kesler and A. D Korczyn Visual disturbances in Parkinson's disease Practical Neurology, February 1, 2006; 6(1): 28 - 33. [Full Text] [PDF]
|
|
|
|
|
|
N. Oishi, F. Udaka, M. Kameyama, N. Sawamoto, K. Hashikawa, and H. Fukuyama Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations Neurology, December 13, 2005; 65(11): 1708 - 1715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. ALLOTT, A. WELLS, A. P. MORRISON, and R. WALKER Distress in Parkinson's disease: contributions of disease factors and metacognitive style The British Journal of Psychiatry, August 1, 2005; 187(2): 182 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Paleacu, E. Schechtman, and R. Inzelberg Association between family history of dementia and hallucinations in Parkinson disease Neurology, May 24, 2005; 64(10): 1712 - 1715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. Stebbins, C. G. Goetz, M. C. Carrillo, K. J. Bangen, D. A. Turner, G. H. Glover, and J. D.E. Gabrieli Altered cortical visual processing in PD with hallucinations: An fMRI study Neurology, October 26, 2004; 63(8): 1409 - 1416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kulisevsky and E. Roldan Hallucinations and sleep disturbances in Parkinson's disease Neurology, October 26, 2004; 63(8_suppl_3): S28 - S30. [Abstract] [Full Text]
|
|
|
|
|
|
D. P. Wint, M. S. Okun, and H. H. Fernandez Psychosis in Parkinson's Disease J Geriatr Psychiatry Neurol, September 1, 2004; 17(3): 127 - 136. [Abstract] [PDF]
|
|
|
|
|
|
D. J. Burn and A. I. Troster Neuropsychiatric Complications of Medical and Surgical Therapies for Parkinson's Disease J Geriatr Psychiatry Neurol, September 1, 2004; 17(3): 172 - 180. [Abstract] [PDF]
|
|
|
|
|
|
J. G. Goldman, C. G. Goetz, E. Berry-Kravis, S. Leurgans, and L. Zhou Genetic Polymorphisms in Parkinson Disease Subjects With and Without Hallucinations: An Analysis of the Cholecystokinin System Arch Neurol, August 1, 2004; 61(8): 1280 - 1284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Marsh, J. R. Williams, M. Rocco, S. Grill, C. Munro, and T. M. Dawson Psychiatric comorbidities in patients with Parkinson disease and psychosis Neurology, July 27, 2004; 63(2): 293 - 300. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. SCHONFELDT-LECUONA and B. J. CONNEMANN Aripiprazole and Parkinson's Disease Psychosis Am J Psychiatry, February 1, 2004; 161(2): 373 - 374. [Full Text] [PDF]
|
|
|
|
|
|
C Colosimo, A J Hughes, L Kilford, and A J Lees Lewy body cortical involvement may not always predict dementia in Parkinson's disease J. Neurol. Neurosurg. Psychiatry, July 1, 2003; 74(7): 852 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Factor, P. J. Feustel, J. H. Friedman, C. L. Comella, C. G. Goetz, R. Kurlan, M. Parsa, R. Pfeiffer, and the Parkinson Study Group Longitudinal outcome of Parkinson's disease patients with psychosis Neurology, June 10, 2003; 60(11): 1756 - 1761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Frucht and L. Bernsohn Visual hallucinations in PD Neurology, December 24, 2002; 59(12): 1965 - 1965. [Full Text] [PDF]
|
|
|
|
|
|
A. J. Harding, E. Stimson, J. M. Henderson, and G. M. Halliday Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease Brain, November 1, 2002; 125(11): 2431 - 2445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Diederich, R. Raman, S. Leurgans, and C. G. Goetz Progressive Worsening of Spatial and Chromatic Processing Deficits in Parkinson Disease Arch Neurol, August 1, 2002; 59(8): 1249 - 1252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jankovic Levodopa strengths and weaknesses Neurology, February 1, 2002; 58(90001): S19 - 32. [Abstract] [Full Text]
|
|
|
|
|
|
R. J. Elble Tremor and dopamine agonists Neurology, February 1, 2002; 58(90001): S57 - 62. [Abstract] [Full Text]
|
|
|
|
|
|
C. R. Cantor and M. B. Stern Dopamine agonists and sleep in Parkinson's disease Neurology, February 1, 2002; 58(90001): S71 - 78. [Abstract] [Full Text]
|
|
|
|
 |
|
 M A Beno tez delRosario, M Feria, and F I M. Alvarez Hallucinations in an elderly cancer patient: opioid neurotoxicity or dementia with Lewy bodies? Palliative Medicine, January 1, 2002; 16(1): 71 - 72. [PDF]
|
|
|
|
|
|
J Barnes and A S David Visual hallucinations in Parkinson's disease: a review and phenomenological survey J. Neurol. Neurosurg. Psychiatry, June 1, 2001; 70(6): 727 - 733. [Abstract] [Full Text] [PDF]
|
|